Kendra Adams's Insider Trades & SAST Disclosures
Kendra Adams's most recent trade in C4 Therapeutics Inc was a trade of 130,600 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kendra Adams.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 130,600 | 130,600 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 87,100 | 169,676 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 13 Feb 2025 | 4,559 | 165,117 | - | 3.2 | 14,498 | Common Stock |
| C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 13 Feb 2025 | 1,863 | 82,576 | - | 3.2 | 5,962 | Common Stock |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 85,541 | - | - | Common Stock | |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 10,500 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.04 per share. | 07 Nov 2024 | 1,102 | 84,439 | - | 6.0 | 6,656 | Common Stock |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.38 per share. | 18 Sep 2024 | 1,837 | 81,791 | - | 6.4 | 11,720 | Common Stock |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 14,250 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 84,289 | - | - | Common Stock | |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.36 per share. | 16 Sep 2024 | 661 | 83,628 | - | 6.4 | 4,204 | Common Stock |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 45,000 | 0 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Adams Kendra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 165,300 | 165,300 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Kendra Adams | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 36,700 | 82,039 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Adams Kendra | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 13 Feb 2024 | 1,301 | 45,339 | - | 6.5 | 8,496 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges